EFM
RLAY icon

E Fund Management’s Relay Therapeutics RLAY Stock Holding History

E Fund Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Buy
24,645
+5,712
+30% +$82.9K 0.01% 291
2026
Q1 		$188K Buy
+18,933
New +$169K 0.01% 453
2025
Q2 		$70.1K Buy
20,258
+1,093
+6% +$3.25K ﹤0.01% 384
2025
Q1 		$50.2K Buy
19,165
+1,511
+9% +$5.92K ﹤0.01% 393
2024
Q4 		$72.7K Buy
17,654
+6,104
+53% +$33.2K ﹤0.01% 386
2024
Q3 		$81.8K Sell
11,550
-228
-2% -$1.7K ﹤0.01% 345
2024
Q2 		$76.8K Sell
11,778
-10,152
-46% -$69.4K ﹤0.01% 310
2024
Q1 		$182K Buy
21,930
+4,444
+25% +$43.4K 0.01% 354
2023
Q4 		$193K Sell
17,486
-1,917
-10% -$16.2K 0.01% 288
2023
Q3 		$163K Sell
19,403
-14,305
-42% -$154K 0.01% 271
2023
Q2 		$423K Buy
33,708
+8,516
+34% +$106K 0.03% 154
2023
Q1 		$415K Buy
25,192
+512
+2% +$9.18K 0.03% 153
2022
Q4 		$369K Buy
24,680
+11,197
+83% +$214K 0.03% 195
2022
Q3 		$302K Sell
13,483
-6,992
-34% -$153K 0.03% 238
2022
Q2 		$343K Buy
20,475
+12,110
+145% +$260K 0.03% 211
2022
Q1 		$250K Buy
+8,365
New +$203K 0.01% 257

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

E Fund Management's RLAY Position: Q2 2026 in Review

E Fund Management increased its Relay Therapeutics (RLAY) stake by 30% in Q2 2026, buying an estimated $82.9K and bringing the position to 24,645 shares worth $461K. The position accounts for 0.01% of the portfolio, ranked #291.

E Fund Management first reported a position in RLAY in Q1 2022 and has held it in 16 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • E Fund Management held 24,645 shares of Relay Therapeutics worth $461K as of Q2 2026.
  • E Fund Management bought 5,712 Relay Therapeutics shares in Q2 2026, an estimated $82.9K.
  • Relay Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #291 holding.
  • E Fund Management first reported a position in Relay Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.